The impact of 18F-FDG-PET-CT findings in the management of a patient with *Mycosis Fungoides*

A. Sabet^{1*}, H.Ahmadzadehfar¹, M. Hildegard Schmid-Wendtner², B. Hinterthaner³, H.J. Biersack¹, S. Ezziddin¹

¹Department of Nuclear Medicine, University Hospital Bonn, Germany ²Department of Dermatology, University Hospital Bonn, Germany ³Department of Radiology, University Hospital Bonn, Germany

Case report

ABSTRACT

In this case we report the detection of lymph node metastases in a 52 years old patient with mycosis fungoides utilising 18F- FDG-PET/CT which led to a change in the management of the patient.

Keywords: 18F-FDG-PET/CT, mycosis fungoides, non-hodgkin lymphoma.

* Corresponding author: Dr. Amir Sabet, Fax: +49 228 2879015184 E-mail: amir.sabet@ukb.uni-bonn.de

Received: Dec. 2011 Accepted: July 2012

Int. J. Radiat. Res., April 2013; 11(2): 127-129

CASE PRESENTATION

A 52 year old man with a known MF and skin patches in both legs for 5 years and a past history of ultraviolet irradiation and Interferontherapy was referred to our department for a restaging with 18F-FDG-PET/CT. The scan was acquired 100 min after intravenous application of 383 MBq 18F-FDG. The blood glucose was 96 mg/dl at the time of injection. Computed tomography was carried out utilising 2-slice spiral CT after intravenous injection of 180 ml solutrast 300 with reconstruction slice-thickness being 2.5 mm. The fused 18F-FDG-PET/CT images demonstrated cutaneous foci of moderate to intense tracer accumulation in both lower extremities especially in the right knee. Furthermore they showed tracer accumulation in inguinal lymph nodes on both sides. In view of

the 18F-FDG-PET/ CT scan findings, the patient was referred for lymph node excision of the right inguinal region, which proved to be metastases in histopathology. Consequently, the patient underwent systemic chemotherapy. A follow-up 18F-FDG-PET/CT scan performed later showed a complete remission with no vital tumour.

DISCUSSION

Mycosis fungoides (MF) is a non-Hodgkin lymphoma of T cell origin that primarily involves the skin. Despite being a rare condition, it is the most common type of cutaneous T cell lymphoma ⁽¹⁾. Most patients present with skin patches or plaques, typically in non-sun-exposed areas ^(2, 3). The staging of patients with MF is based primarily on the extent of skin disease, type of

Sabet et al. / PET-CT of a patient with Mycosis Fungoides

skin lesion, and involvement of extracutaneous sites, such as lymph nodes (LN), viscera, and peripheral blood $^{(4,5)}$.

Positron emission tomography (PET) and PET/computed tomography (PET/CT) have emerged as the standard of care for the staging, monitoring of response to therapy, and detection of disease recurrence for Hodgkin's (HD) and non Hodgkin's lymphomas (NHL) ⁽⁶⁻¹⁰⁾. A review of a series of 13 patients with MF has demonstrated the superiority of PET/CT over CT alone in detecting nodal involvement ⁽¹¹⁾. Accurate staging is important for prognostic purposes and to determine appropriate treatment options ⁽²⁾. Treatment of MF varies

according to the stage of the disease. Early-stage MF is highly responsive to topical treatments such as topical chemotherapy, ultraviolet irradiation (psoralen + UVA) and immunomodulatory agents such as interferon and retinoids ⁽¹⁾. In contrast systemic disease requires more aggressive and potentially more toxic therapy such as systemic chemotherapy or total-skin electron beam therapy ⁽²⁾. Our patient underwent systemic chemotherapy only due to 18F-FDG-PET/CT findings. This shows the significance of 18F-FDG-PET/CT in the therapeutic management of MF and may eventually help to establish its value in staging of this rare disease.



Figure 1. Cutaneous tracer accumulation in the right knee (a) sagittal view (b) transversal view.



Figure 2. Inguinal lymph nodes on both sides, (a) PET image coronal view, (b) PET-CT image transversal view, (c) CT image transversal view.

Int. J. Radiat. Res., Vol. 11 No. 2, April 2013

Sabet et al. / PET-CT of a patient with Mycosis Fungoides

REFERENCES

- 1. Rupoli S, Goteri G, Pulini S, Filosa A, Tassetti A, Offidani M, et al. (2005) Long-term experience with lowdose interferon-alpha and PUVA in the management of early mycosis fungoides. *Eur J Haematol*, **75**: 136-45.
- 2. Foss F (2004) Mycosis fungoides and the Sezary syndrome. *Curr Opin Oncol,* 16: 421-8.
- Girardi M, Heald PW, Wilson LD (2004) The pathogenesis of mycosis fungoides. N Engl J Med, 350: 1978-88.
- 4. Vonderheid EC, Bernengo MG (2003) The Sezary syndrome: hematologic criteria. *Hematol Oncol Clin North Am*, **17**:1367-89.
- Bunn PA, Jr., Lamberg SI (1979) Report of the Committee on Staging and Classification of Cutaneous T-Cell Lymphomas. *Cancer Treat Rep*, 63: 725-8.
- Bangerter M, Moog F, Buchmann I, Kotzerke J, Griesshammer M, Hafner M, *et al.* (1998) Whole-body 2-[18F]-fluoro-2-deoxy-D-glucose positron emission tomography (FDG-PET) for accurate staging of Hodgkin's disease. *Ann Oncol*, *9:* 1117-22.

- Buchmann I, Moog F, Schirrmeister H, Reske SN (2000) Positron emission tomography for detection and staging of malignant lymphoma. *Recent Results Cancer Res*, 156: 78-89.
- Buchmann I, Reinhardt M, Elsner K, Bunjes D, Altehoefer C, Finke J, *et al.* (2001) 2-(fluorine-18)fluoro -2-deoxy-D-glucose positron emission tomography in the detection and staging of malignant lymphoma. A bicenter trial. *Cancer*, *91:* 889-99.
- 9. Jerusalem G, Hustinx R, Beguin Y, Fillet G (2005) Evaluation of therapy for lymphoma. *Semin Nucl Med*, **35:** 186-96.
- Valencak J, Becherer A, Der-Petrossian M, Trautinger F, Raderer M, Hoffmann M (2004) Positron emission tomography with [18F] 2-fluoro-D-2- deoxyglucose in primary cutaneous T-cell lymphomas. *Haematologica*, 89: 115-6.
- 11. Tsai EY, Taur A, Espinosa L, Quon A, Johnson D, Dick S, *et al.* (2006) Staging accuracy in mycosis fungoides and sezary syndrome using integrated positron emission tomography and computed tomography. *Arch Dermatol*, **142**: 577-84.